Globally, lung cancer is the leading cause of cancer deaths, numbering over 150,000 deaths each year in the US alone. Despite the high incidence and death rate with this type of cancer, screening options remain limited and costly to implement for high-risk individuals. Often, lung cancer is diagnosed in late stages of the disease, limiting treatment options and lowering the rate of survival. Currently, the most commonly used method of screening on the market is Low-Dose Computed Tomography. Though effective, this method suffers from low availability and still exposes patients to high doses of radiation, which results in low follow-up numbers.